메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Asian Smart Medical Online Exhibition 2026: Connecting Smart Medical Suppliers with Global Buyers

TAIPEI, Feb. 5, 2026 -- The Asian Smart Medical Online Exhibition 2026 (Medical Asia 2026) is a premier hybrid exhibition designed to seamlessly connect Asian medical suppliers, importers, and exporters with buyers from around the world. Taking place from February 3, 2026, to May 31, 2026, Medical Asia 2026, this four-month online exhibition provides exhibitors with an exceptional platform to showcase their brands, products, and innovations to a truly global audience. Organized by AsianNet and TradeAsia (www.e-tradeasia.com), Medical Asia has been successfully facilitating inte
- 김갑성 기자
- 2026-02-05 09:05
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

SHANGHAI, Feb. 5, 2026 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. ("Micot") to commercialize MT1013, the world's first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) re
- 김갑성 기자
- 2026-02-05 08:17
Finally, a Natural Alternative to Acacia Gum in Beverages

RIVER FALLS, Wis., Feb. 5, 2026 -- Fiberstar, Inc., the leader of innovative citrus fibers launched an all-natural alternative to acacia gum – Citri-Fi® Pro. For decades, the beverage industry has been searching for an acacia gum replacement due to the geopolitical instability in the Sudan region which is causing humanitarian crises thus posing a question surrounding ethical sourcing. The beverage industry uses acacia gum (gum arabic) extensively to create emulsions. "This new acacia gum alternative, Citri-Fi Pro, comes at a time when beverage makers are desperately se
- 김갑성 기자
- 2026-02-04 23:19
음료용 아카시아 고무를 대체할 새로운 천연 대체제 등장

리버폴스, 위스콘신 , 2026년 2월 5일 -- 혁신적인 감귤 식이섬유 분야의 선도 기업 파이버스타(Fiberstar, Inc.)가 아카시아 고무의 천연 대체재인 Citri-Fi® Pro를 출시했다. 수십 년간 음료 업계는 수단 지역의 지정학적 불안정으로 인한 인도적 위기와 윤리적 조달 문제로 인해 아카시아 고무 대체 원료를 모색해 왔다. 음료 업계에서는 유화(emulsion)를 형성하기 위해 아카시아 고무(아라비아검)을 광범위하게 사용하고 있다. 파이버스타의 존 헤인(John Haen) 사장 겸 최고경영자는 "이번에 출시한 아카시아 고무 대체재인 Citri-Fi Pro는 음료 제조사들이 절실히 대체 원료를 찾고 있는 시점에 맞춰 선보이게 됐다"고 밝혔다. 이어 "제안된 EU 기업 지속가능성 실사 지침(Corporate Sustainability Due Diligence Directive, CSDDD)과 같은 지침은 대기업이 글로벌 운영 및 공급망 전반에서 인권 및 환경 리스크 식별 및 완화를 의무화할 것이며, 이는 향후 분쟁 지역에서 아카시아 고무를 조달하는 데 직접적인 영향을 미칠 것&qu
- 김갑성 기자
- 2026-02-04 23:19
Yuyu Pharma Invests in James & Ella, Advancing Its Global Expansion Into Premium Pet Wellness

SEOUL, South Korea, Feb. 4, 2026 -- Yuyu Pharma announced today a strategic investment in James & Ella, the United Kingdom's fastest-growing freeze-dried pet nutrition company. Founded by entrepreneur James Middleton, James & Ella has rapidly established itself as the leader of the UK freeze-dried category, with nationwide distribution through Sainsbury's, Waitrose, Ocado, and Amazon UK, supported by a strongly expanding direct-to-consumer subscription channel. This investment reflects Yuyu Pharma's expanding global focus on premium pet wellness. Freeze-dr
- 김갑성 기자
- 2026-02-04 22:00
NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 4, 2026 -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Veradermics (NYSE: MANE), a hair loss biotech company, set for NYSE trading debut Ashley Mastronardi delivers the pre-market update on February 4th Stocks are moving higher early Wednesday as traders rotate into economically sensitive sectors. Small-cap stocks have b
- 황정호 기자
- 2026-02-04 21:56
Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial

[ 메디채널 김갑성 기자 ] Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. CALGARY, AB and BRISBANE, Australia , Feb. 5, 2026 -- Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors. The PaedNEO-VAX trial, funded by Providence Therapeutics, in combination with the Australian Government and a host of philanthropic donors, is th
- 김갑성 기자
- 2026-02-04 21:00
NCCN Commemorates World Cancer Day with New Commitment to Update Patient Resources

[ 메디채널 김갑성 기자 ] The National Comprehensive Cancer Network pledges to update robust information resources for cancer patients and caregivers on an annual basis in both English and Spanish. PLYMOUTH MEETING, Pa., Feb. 4, 2026 -- [ 메디채널 김갑성 기자 ] The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers based in the United States—and the NCCN Foundation® is honoring World Cancer Day with an announcement about more frequent updates to its free educational resources intended to empower shared decision-making. World Cancer Day is a
- 김갑성 기자
- 2026-02-04 20:04
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit alert for the year ended December 31, 2025. Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, total profit is expected to range between US$88 million (equivalent to approximately HK$685 million) and US$95 million (equivale
- 김갑성 기자
- 2026-02-04 08:01
Telix Full Year Results 2025 Investor Webcast Notification

MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026 EST). An investor webcast and conference call will be held at 9:30 a.m. AEDT, Friday 20 February 2026 (5:30 p.m. EST, Thursday 19 February 2026). Participants can register at the following link: https://edge.media-server.com/mmc/p/famdpwzh About Telix Pharmaceuticals Limited &nbs
- 김갑성 기자
- 2026-02-04 05:38

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-03-02_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 03월 03일 01시 00분